Myeloma Investment Fund
Deals on record
1
Common Fundraising Type
Equity
Indapta Therapeutics
Biotechnology
Indapta Therapeutics develops allogeneic Natural Killer (NK) cell therapies for treating cancer and autoimmune diseases.
Deals on record
Common Fundraising Type
Biotechnology
Indapta Therapeutics develops allogeneic Natural Killer (NK) cell therapies for treating cancer and autoimmune diseases.